AU2019356940A1 - Uses of modified RNA encoding retinaldehyde dehydrogenase - Google Patents
Uses of modified RNA encoding retinaldehyde dehydrogenase Download PDFInfo
- Publication number
- AU2019356940A1 AU2019356940A1 AU2019356940A AU2019356940A AU2019356940A1 AU 2019356940 A1 AU2019356940 A1 AU 2019356940A1 AU 2019356940 A AU2019356940 A AU 2019356940A AU 2019356940 A AU2019356940 A AU 2019356940A AU 2019356940 A1 AU2019356940 A1 AU 2019356940A1
- Authority
- AU
- Australia
- Prior art keywords
- virus
- vaccine
- protein
- raldh
- species
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7115—Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0008—Oxidoreductases (1.) acting on the aldehyde or oxo group of donors (1.2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/44—Oxidoreductases (1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y102/00—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2)
- C12Y102/01—Oxidoreductases acting on the aldehyde or oxo group of donors (1.2) with NAD+ or NADP+ as acceptor (1.2.1)
- C12Y102/01036—Retinal dehydrogenase (1.2.1.36)
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Mycology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862743943P | 2018-10-10 | 2018-10-10 | |
| US62/743,943 | 2018-10-10 | ||
| PCT/US2019/055543 WO2020077045A1 (en) | 2018-10-10 | 2019-10-10 | Uses of modified rna encoding retinaldehyde dehydrogenase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2019356940A1 true AU2019356940A1 (en) | 2021-05-13 |
Family
ID=70164700
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019356940A Abandoned AU2019356940A1 (en) | 2018-10-10 | 2019-10-10 | Uses of modified RNA encoding retinaldehyde dehydrogenase |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20210338709A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3863646A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2022512686A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019356940A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3115522A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020077045A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2023008986A (es) * | 2021-01-29 | 2023-08-15 | Inst Nat Sante Rech Med | Polipeptidos antigenicos de chlamydia trachomatis y usos de los mismos con fines de vacuna. |
| TW202615065A (zh) * | 2024-08-09 | 2026-04-16 | 日商第一三共股份有限公司 | mRNA疫苗佐劑 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060263340A1 (en) * | 2005-04-29 | 2006-11-23 | Andrian Ulrich H V | Treating gastrointestinal diseases with modulators of retinoic acid |
| EP2753362A4 (en) * | 2011-09-08 | 2015-04-15 | Univ Florida | MATERIALS AND METHOD FOR MODULATING IMMUNE SYSTEM REACTIONS |
| US20160051669A1 (en) * | 2014-08-21 | 2016-02-25 | Georgia Regents University Research Institute, Inc. | Compositions and methods for selectively modulating tregs |
| US10238741B2 (en) * | 2014-10-10 | 2019-03-26 | The Trustees Of Columbia University In The City Of New York | Nucleic acid constructs for presentation of CD4 and CD8 epitopes, cellular transfection and uses thereof |
| CA2975432A1 (en) * | 2015-02-13 | 2016-08-18 | Transgene Sa | Immunotherapeutic vaccine and antibody combination therapy |
| ES2893584T3 (es) * | 2015-06-10 | 2022-02-09 | Univ Tokyo | Adyuvante para vacunas, vacuna y procedimiento de inducción de inmunidad |
| WO2017191274A2 (en) * | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
-
2019
- 2019-10-10 AU AU2019356940A patent/AU2019356940A1/en not_active Abandoned
- 2019-10-10 EP EP19871482.6A patent/EP3863646A4/en active Pending
- 2019-10-10 CA CA3115522A patent/CA3115522A1/en active Pending
- 2019-10-10 WO PCT/US2019/055543 patent/WO2020077045A1/en not_active Ceased
- 2019-10-10 JP JP2021520209A patent/JP2022512686A/ja active Pending
- 2019-10-10 US US17/284,212 patent/US20210338709A1/en not_active Abandoned
-
2025
- 2025-07-18 US US19/273,379 patent/US20250339458A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP3863646A1 (en) | 2021-08-18 |
| EP3863646A4 (en) | 2022-09-28 |
| US20250339458A1 (en) | 2025-11-06 |
| WO2020077045A1 (en) | 2020-04-16 |
| CA3115522A1 (en) | 2020-04-16 |
| JP2022512686A (ja) | 2022-02-07 |
| US20210338709A1 (en) | 2021-11-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250339458A1 (en) | Uses of modified rna encoding retinaldehyde dehydrogenase | |
| JP7675052B2 (ja) | Rnaの投与のための配合物 | |
| CN108430456B (zh) | 癌症疫苗 | |
| JP2023082121A (ja) | Rnaの投与のための配合物 | |
| CN109072232A (zh) | 用于提供单链rna的方法 | |
| JP2025503994A (ja) | コロナウイルスワクチン | |
| US20260062716A1 (en) | Lipid nanoparticle (lnp) composition or formulation for nucleic acid therapeutics | |
| CN119968210A (zh) | 用于预防或治疗结核病的rna | |
| JP2023175686A (ja) | ヒト免疫応答をモジュレートするためのイミダゾピリミジンの使用 | |
| JP2024517642A (ja) | ウイルスワクチン | |
| US11633473B2 (en) | Stimulator of Interferon Genes (STING) ligands and uses thereof | |
| CN117460827A (zh) | 狂犬病核酸疫苗 | |
| AU2012229234B2 (en) | Vaccine formulation of mannose coated peptide particles | |
| US20250041278A1 (en) | Tlr8 agonist for modulating immune response | |
| US20250000971A1 (en) | Tlr4 agonist for modulating immune response | |
| EP3057981A1 (fr) | Vaccin thérapeutique contre le cancer à base de protéines de stress rendues immunogènes | |
| Gómez-Aguado | 3.2 Nucleic acid delivery systems | |
| HK40102659A (en) | Virus vaccine | |
| WO2026082899A2 (en) | Rna for preventing or treating tuberculosis | |
| CN118176209A (zh) | 涉及用于抗原疫苗接种的非免疫原性rna和pd-1轴结合拮抗剂的治疗 | |
| WO2024196771A2 (en) | Lipid gb3 as adjuvant for vaccination | |
| Genito | Generation of Immune Tolerance with Combined Pharmacological Agents | |
| CN117615752A (zh) | 包含缓冲物质的rna组合物及其制备、储存和使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |